#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Theo Mastrokostopoulos Email
VP Sales & Market Development . LimFlow
Paris,
Locationt*****************@limflow.com
Primary EmailHow to contact Theo Mastrokostopoulos
Join and see Theo's contact info for free!Current Roles
Employees:
54Revenue:
$13.6MAbout
LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage Critical Limb Ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. CLI is the most severe form of peripheral artery disease (PAD) and often occurs in patients suffering from coronary artery disease, diabetes, obesity, high cholesterol and high blood pressure. Patients with this chronic disease experience profound, chronic pain and if untreated can develop festering wounds or infections that lead to major limb amputation, an event closely associated with increased mortality and reduced quality of life. To relieve the symptoms of CLI, patients are typically treated with Percutaneous Transluminal Angioplasty (PTA) or with open and complex Distal Bypass Surgery (DBS). In many late-stage patients, neither option is feasible due to extensive disease in the target arteries or other anatomical constraints. The LimFlow procedure reinvents the anatomy in a percutaneous treatment that diverts blood around diseased arteries and into the tibial vein to perfuse an ischemic foot. Our proprietary technologies and expertise enable Vascular Specialists to provide new hope for their "Desert Foot" patients by delivering high levels of oxygenated blood flow hence promoting wound healing and reduced amputation rates.LimFlow Address
3031 Tisch WayParis, null
France